Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF) (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $254000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 15.33% to $254000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 12.17% year-over-year, with the annual reading at $1.1 million for FY2025, 8.33% down from the prior year.
  • Depreciation & Amortization (CF) hit $254000.0 in Q4 2025 for Taysha Gene Therapies, up from $200000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q2 2023 to a low of $200000.0 in Q3 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $306062.5 across 4 years, with a median of $300000.0 in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 33.33% in 2023 and later crashed 33.33% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $372000.0 in 2022, then fell by 0.27% to $371000.0 in 2023, then dropped by 19.14% to $300000.0 in 2024, then fell by 15.33% to $254000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for TSHA at $254000.0 in Q4 2025, $200000.0 in Q3 2025, and $300000.0 in Q2 2025.